Skip to content

Clinical study on reducing the recurrence of chronic spontaneous urticaria with Gubenkangmin prescription

Clinical study on reducing the recurrence of chronic spontaneous urticaria with Gubenkangmin prescription

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006796
Enrollment
Unknown
Registered
2022-11-18
Start date
2022-12-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic urticaria

Interventions

control group:cetirizine hydrochloride
treatment group:Gubenkangmin prescription

Sponsors

Guangdong Provincial Hosptial of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients who meet the chronic spontaneous urticaria diagnosis creteria and urticaria activity score weekly(UAS7)=16; 2. Male and female aged 18 to 65 years old; 3. Patients with syndrome pattern of Wei qi deficiency; 4.To be able to and willing to provide signed informed consent.

Exclusion criteria

Exclusion criteria: (1)those with severe acute attack of urticaria , appearing with chest tightness, asthma, dyspnea,asphyxia or other life-threatening symptoms such as high fever, shivering, pulse speed and so on; (2)those who are pregnant ,lactating or prepared for pregnancy within the next six months ; (3)suffering from serious mental disorders; (4)suffering from other skin disorders which need treatment at the same time;or with severe primary diseases concerned about circulatory system, respiratory system, digestive system, urinary system, endocrine system ,hematopoietic system or with therioma, beyond the control of conventional treatment;or with obvious abnormal medical examination results:such as increase of alanine aminotransferase(ALT) or aspartate aminotransferase(AST)>treble the normal upper limit,increase of creatinine>treble the normal upper limit; (5)antihistamines or Chinese medicine were used within 1 week before entering the study, steroids hormone(oral medication),immunoglobulin, immunosuppressive drugs ,autohemotherapy were used within 4 weeks ,biologics and steroids hormone(injection) were used within 12 weeks; (6) allergy to drugs used in this study; (7) involved in other clinical studies at the same time or in the last 4 weeks. (8)people whose job require high concentration (9)Patients should not be enrolled according to the judgment of their physician

Design outcomes

Primary

MeasureTime frame
recurrence rate;

Secondary

MeasureTime frame
recurrent times;chronic urticaria quality of life questionnaire;recurrence interval;Urticaria Control Test (UCT);urticaria activity score weekly(UAS7);

Countries

china

Contacts

Public ContactJie Guo
1016877723@qq.com15013075252

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026